Clinical Trials Sponsored by Ardana Bioscience Ltd

Total 439 results

Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Hodgkin Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Limited-stage Small Cell Lung Cancer (LS-SCLC)

China, France, United States, Spain, Taiwan, Korea, Republic of, Turkey, Italy, Netherlands, Georgia, Germany, Belgium, Poland, Romania
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study of 7MW3711 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
Guangzhou Henovcom Bioscience Co. Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

Parkinson's Disease

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections

Skin Infection

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

Wet Age-related Macular Degeneration

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm

Advanced Malignant Neoplasm

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Clinical Study of JS201 in Patients With Advanced Malignant Tumors

Patients With Advanced Malignant Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Melanoma | Urothelial Carcinoma | Renal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Locally Advanced or Metastatic Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Non-small Cell Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Active, not recruiting

Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

Healthy

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Advanced Cancer

China
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

IPF

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment (JS001)

NSCLC

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

Nasopharyngeal Carcinoma | Head and Neck Squamous Cell Carcinom

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19

COVID-19

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Phase I Study of JS108 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Active, not recruiting

An Evaluation of 9MW1911 Injection in Healthy Subjects

Asthma | Atopic Dermatitis | COPD

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (TORCHLIGHT)

Triple-Negative Breast Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

Moderate to Severe Psoriasis

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Breast Cancer Female

China
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

Healthy

United States
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

NSCLC

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Mucosal Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Participants With Advanced Solid Tumors

Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Melanoma | Urological Cancer

China
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Healthy

United States
Blaze Bioscience Australia Pty Ltd

Completed

Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Skin Neoplasms

Australia
Enzene Biosciences Ltd.
Alkem Laboratories Ltd

Recruiting

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

Postmenopausal Osteoporosis

Czechia
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants (XW003)

Obesity | Type 2 Diabetes Mellitus | Nonalcoholic Steatohepatitis

Australia
Shanghai Junshi Bioscience Co., Ltd.
CTI Clinical Trial and Consulting Services; TopAlliance Biosciences, Inc.

Withdrawn

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Malignancies | Previously Treated, Advanced
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.

Not yet recruiting

XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Obesity | Type 2 Diabetes Mellitus

Australia
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

Obesity

Australia
Ardea Biosciences, Inc.
Quotient Clinical

Completed

IVIVR Assessing PK Parameters Used to Establish Bioequivalence

Healthy

United Kingdom
Hangzhou Hanx Biopharmaceuticals, Ltd.
Wuhan Hanxiong Bioscience, Ltd.

Active, not recruiting

The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China

3

Subscribe